Please assess the completion status of the following clinical trial:

Trial Title: JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
* Inclusion Criteria: Subjects must satisfy all the following criteria.~  1. Male or female, ≥ 19 years of age at the time of obtaining consent~ 2. Subjects who had experienced heartburn and regurgitation within 7 days prior to the screening visit, those whose severity and frequency of symptoms fall under the following (1) or (2)~     ⑴ Subjects who have experienced mild or more severe heartburn or regurgitation at least twice a week~     ⑵ Subjects who have experienced moderate or more severe heartburn or regurgitation at least once a week~ 3. Endoscopically confirmed grade A or higher erosive esophagitis as defined by †LosAngeles classification within 15 days, prior to randomization~ 4. Subjects who fully understand this study and voluntarily signed on the informed consent form~* Exclusion Criteria: Subjects may not satisfy any of the following criteria.~  1. Subjects who can't undergo endoscopy~ 2. Medical History~     º Subjects who have warning symptoms of the malignant gastrointestinal tract such as odynophagia, severe dysphagia, bleeding, weight loss, anemia, or bloody stool. (except negative result for malignancy by endoscopy)~     º Subjects with eosinophilic esophagitis (except negative result by esophageal biopsy)~     º Subjects who have esophageal stenosis, gastroesophageal varices, Barrett's esophagus, active gastric ulcer, gastrointestinal bleeding, or malignant tumor confirmed by EGD~     º Zollinger-Ellison syndrome patients~     º Subjects diagnosed with primary esophageal motility disorder, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), or suspected with IBS in the last 3 months and with a current history of the disease including pancreatitis~     º Subjects who have a history of gastric acid suppression surgery, gastrointestinal or esophageal surgery (except appendectomy, cholecystectomy, polypectomy)~     º Subjects with a history of clinically significant hepatic, renal, cardiovascular, respiratory, endocrine, urinary, neuro-psychiatric, hemato-oncologic disorder~     º Subjects who have a history of malignant tumor in 5 years at the time of screening. However, excluding subjects with malignant gastrointestinal cancer regardless of the period.~ 3. Laboratory Test~     Screening laboratory test showing any of the following abnormal laboratory results:~     º ALT or AST \> 2.0 x ULN~     º ALP or GGT \> 2.0 x ULN~     º Total bilirubin \> 2.0 x ULN~     º eGFR\<70 mL/min/1.73 m2 (CKD-EPI formula)~     º Positive result for Serological test (HBsAg, HCV Ab, HIV Ab, Syphilis reagin test)~     º Clinically significant ECG abnormalities~ 4. Allergy and drug hypersensitivity~     º Known hypersensitivity to the active ingredient or excipients of the investigational product~     º Clinically significant allergies (except mild allergic rhinitis) or hypersensitivity history to drugs. (Aspirin, antibiotics, etc.)~ 5. Prohibited medication and therapy~     º Subjects who take gastric acid suppressant like P-CAB, PPI within 2weeks prior to EGD of screening procedure~     º Subjects who take medication (antacids, prokinetics, H2RA, etc.) related to reflux esophagitis more than 2times within 1week prior to EGD of screening procedure~     º Subjects who need to take medication (aspirin, NSAIDs, etc.) that may cause an ulcer, during the study period~     º Subjects who are on or need to be on the medications which categorized as contraindicated in this clinical trial.~     However, subjects who are on the contraindicated medications can participate in the trial after the washout period of 2 weeks. If five times of the half-life of the contraindicated medications exceeds 2 weeks, the washout period will be set as five times of the half-life.~ 6. Pregnant and lactating women~ 7. Contraception Subjects who do not agree to use medically acceptable methods of contraception during the period study~ 8. Subjects with clinically significant psychiatric disorder and a history with a drug and alcohol abuse.~ 9. Subjects who are judged unsuitable to participate in the study in the opinion of the investigator

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental Group (Type: EXPERIMENTAL): JP-1366 20mg + Esomeprazole 40mg(placebo)
- Active Comparative Group (Type: ACTIVE_COMPARATOR): JP-1366 20mg(placebo) + Esomeprazole 40mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete